Tracy Neal, MD
Cardiovascular Disease · Cullman, ALNPI 1881664258
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,467 of the $6,323 with a category attached, or 86.4%. 36 manufacturers reported payments, led by Medtronic at 24.6% of the total.
Across 288 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Merck$774
- Novartis$768
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$424
- E.r. Squibb & Sons, L.L.C.$419
- Abbott$308
- plus $2K from 30 others
Across 2 payments — averaging $414,599 each. An ownership or investment interest held by the physician or an immediate family member.
- Corvista Health, Inc.$829K
What the payments were for
- Travel & lodging$85714%
- Food & beverage$5,46786%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 27 | $1,556 |
| Merck | 35 | $774 |
| Novartis | 64 | $768 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $424 |
| E.r. Squibb & Sons, L.L.C. | 14 | $419 |
| Abbott | 11 | $308 |
| Pfizer | 18 | $299 |
| Amgen | 17 | $240 |
| AstraZeneca | 12 | $154 |
| Sanofi-aventis U.S. LLC | 9 | $150 |
| Cvrx, Inc. | 2 | $136 |
| Boehringer Ingelheim | 5 | $101 |
| Bayer | 5 | $98 |
| Novo Nordisk | 4 | $95 |
| Lantheus Medical Imaging, Inc. | 5 | $83 |
| Alnylam Pharmaceuticals Inc. | 5 | $78 |
| Johnson & Johnson | 4 | $71 |
| Philips North America LLC | 4 | $61 |
| Boston Scientific | 1 | $60 |
| Corvista Health, Inc. | 1 | $59 |
| Elutia, Inc. | 1 | $53 |
| Medicomp Inc | 3 | $45 |
| Regeneron Healthcare Solutions, Inc. | 3 | $43 |
| Irhythm Technologies, Inc. | 2 | $32 |
| Medline Industries LP | 1 | $24 |
| Convatec Inc. | 1 | $24 |
| Vital Connect, Inc | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| GE HealthCare | 1 | $19 |
| Cleerly, Inc. | 1 | $18 |
| Terumo Medical Corporation | 1 | $18 |
| Osprey Medical Inc | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
| G Medical Diagnostic Services, Inc. | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $13 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$857
- CAMZYOS$125
- Barostim Neo System$124
- AZURE XT DR MRI SURESCAN$118
- ASSURITY$113
How this compares
$6,323 in reported general payments places this provider in the 70th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 498 | $423,490 |
| EntrestoSacubitril/Valsartan | 210 | $232,165 |
| FarxigaDapagliflozin Propanediol | 94 | $74,771 |
| XareltoRivaroxaban | 69 | $54,032 |
| Repatha SureclickEvolocumab | 48 | $40,945 |
| MultaqDronedarone Hcl | 13 | $19,676 |
| BrilintaTicagrelor | 18 | $17,853 |
| Ranolazine ErRanolazine | 82 | $14,990 |
| Praluent PenAlirocumab | 12 | $7,879 |
| Metoprolol Succinate | 254 | $4,714 |
| Amiodarone Hcl | 64 | $2,699 |
| Atorvastatin Calcium | 148 | $2,578 |
| Carvedilol | 257 | $2,285 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 71 | $2,279 |
| PradaxaDabigatran Etexilate Mesylate | 12 | $2,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $299 | $423,490498 claims |
| NovartisEntresto | $768 | $232,165210 claims |
| AstraZenecaFarxiga, Brilinta | $154 | $92,624112 claims |
| Johnson & JohnsonXarelto | $71 | $54,03269 claims |
| Sanofi-aventis U.S. LLCMultaq | $150 | $19,67613 claims |
| Boehringer IngelheimPradaxa | $101 | $2,26112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Cullman
- Dennis ThomasMobile$894K
- David FienoAlabaster$421K
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Ajit NaiduFlorence$66K
- Mahomed SalameAnniston$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.